2020 Year in Review - Non–Small-Cell Lung Cancer

Over the past year, the COVID-19 pandemic has ushered in unprecedented changes in the practice of medicine and dissemination of treatment advances presented in scientific forums. Read More ›

Overall response rate, duration of response, and media progression-free survival were highest in the group of treatment-naïve patients with T790M negativity and any MET mutation. Read More ›

US Food and Drug Administration–approved capmatinib is an effective second-line treatment for patients with MET exon 14–mutated NSCLC. Read More ›

First-line treatment with ramucirumab plus erlotinib in patients with EGFR-mutated metastatic NSCLC was associated with superior progression-free survival compared with erlotinib plus placebo. Read More ›

Lorlatinib is associated with longer progression-free survival and a higher overall and intracranial response rates among patients with previously untreated, advanced ALK-positive NSCLC. Read More ›

Selpercatinib and pralsetinib are US Food and Drug Administration–approved treatment options for patients with RET fusion–positive NSCLC. Read More ›

[Fam-]trastuzumab deruxtecan shows promising clinical activity with a high and durable response rate in patients with HER2-mutated NSCLC.

Read More ›

Treatment with gefitinib in the adjuvant setting is associated with enhanced quality of life in patients with early-stage NSCLC and EGFR mutations. Read More ›

Ensartinib may be a viable treatment option for some forms of secondary ALK alterations. Read More ›

Similar progression-free survival and 2-year overall survival rates reported for both treatment groups, with more grade ≥3 treatment-related adverse events reported in the afatinib + cetuximab group. Read More ›